



Primary Malignant Germ-Cell Tumors of the Anterior Mediastinum in Adults Report of Two Rare Cases and Review of the Literature

Stavros Daliakopoulos I*, Maria Stergianni, Grigorios Karagkiouzis, Antonella Koutela, Dimitrios Pappas, Christos Tsakalakis and Charalampos Martinos

Department of Cardiothoracic Surgery, Veterans Military Hospital of Athens, Metropolitan General Hospital, Greece

Abstract

Introduction: Malignant germ-cell tumors are usually located in the gonads. Extragonadal germ-cell tumors are extremely rare and are typically located in midline structures and, especially, the anterior mediastinum. They are divided into seminomas and non-seminomatous germ cell tumors. The former is a radiosensitive tumor that can be successfully treated by surgery and radiation. The latter is a very rare category including: Yolk Sac Tumor (YST), Embryonal Carcinoma (EC), Choriocarcinoma (CC) and Combined Germs Cell Tumors (CGCTs). These tumors with relatively unknown clinical behavior are uncommon neoplasm of the mediastinum and only sporadic cases have been documented in the literature.

Case Presentation: We report two male patients referred to our team with huge bulky tumors of the anterior mediastinum, infiltrating into adjacent anatomical structures for consultation and management. At the time of admission one of the patients presented with grossly edematous upper extremities and engorged cervical veins suggesting Superior Vena Cava (SVC) syndrome. The patients were treated surgically at first instance, for different medical reasons each, the unusual neoplasms with the different biologic behavior were totally excised or not, according to each case surgical demands and the systemic manifestations of the neoplasms were reversed.

Conclusion: Malignant germ cell tumors are suspected among anterior mediastinal tumors affecting male patients of around 20 years old. Tumor markers must be investigated and tissue histology should be diagnosed for specimens obtained by mediastinoscopy or anterior mediastinotomy. In case of Non-Seminomatous Germ Cell Tumors (NSGCT) or α -Fetoprotein and/or humane Choriongonadotropin producing seminoma, the first choice remains chemotherapy. Means for surgical decision making are based only on dramatically worsening clinical indicators of SCV syndrome because initial debulking surgery is rarely useful.

Keywords: Anterior mediastinum; Yolk sac tumor; Primary malignant Germ-Cell tumors

Abbreviations

YST: Yolk Sac Tumor; EC: Embryonal Carcinoma; CC: Choriocarcinoma; CGCTs: Combined Germs Cell Tumors; SVC: Superior Vena Cava; NSGCT: Non-Seminomatous Germ Cell Tumors; AFP: α -Fetoprotein; β -HCG: Beta Human Chorionic Gonadotropin; BEP: Bleomycin-Etoposide-Cisplatin; TIP: Regimen Paclitaxel-Ifosfamide-Cisplatin

Introduction

The posterior mediastinum presents a tendency to develop metastatic tumors especially gonadic ones, because of the lymphatic drainage of the testes and the thoracic aorta in the posterior mediastinal, whereas anterior mediastinal space characterized by tumour growth of primary aetiology [1].

The region of the rare presence of primary seminoma is the pineal body, the mediastinum and the retroperitoneum. The mediastinal region is the most common site of seminoma. The latter is in the anterior mediastinum, involves predominantly young males and corresponds to 25% to 30% of malignant mediastinal germ cell tumors [2,6]. The thymus gland is often the primary hosts of mediastinal seminoma [7,8]. Even if there are supporters of thymic genetic origin of the primary seminoma, the latest theory professes ectopic seminoma of a tumour originating in the gonads [9].

OPEN ACCESS

*Correspondence:

Stavros Daliakopoulos I, Department of Cardiothoracic Surgery, Veterans Military Hospital of Athens, Hellas, Metropolitan General Hospital–Athens Interbalkan Medical Center-Thessaloniki, Greece, Tel: +306947429559; +4915209069847; E-mail: sdaliakopoulos@live.com

Received Date: 11 Jun 2019

Accepted Date: 23 Jul 2019

Published Date: 29 Jul 2019

Citation:

Stavros Daliakopoulos I, Stergianni M, Karagkiouzis G, Koutela A, Pappas D, Tsakalakis C, et al. Primary Malignant Germ-Cell Tumors of the Anterior Mediastinum in Adults Report of Two Rare Cases and Review of the Literature. *Clin Surg*. 2019; 4: 2518.

Copyright © 2019 Stavros Daliakopoulos I. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Image 1: Yolk sac tumor. The initial chest radiograph demonstrating soft tissue fullness along the right hilum and mediastinum that obscures the hilar anatomy.



Image 2: CT-axial plan of a large Yolk sac tumor in the anterior mediastinum invading the art. Carotis communis. White arrow pointing low attenuation foci, suggesting central necrosis.



Image 3: CT-axial plan of the Yolk sac tumor.




Image 4: CT-axial plan demonstrating a 10cm Yolk sac tumor invading the truncus pulmonalis and the vena cava superior.

Additionally, yolk sac tumour is a germ cell tumour which behave as a mixed tumour within other tumors of the same category as teratoma (35%), or as an extremely rare pure solitary one like in our

case [10,11].

Two interesting rare cases presented in this report which concern two categories of germ cell tumors: mediastinal seminoma and pure yolk sac tumour.

Case Series

Case - 1

The 1st case we report is of a 22-year-old Caucasian male, who was admitted to our hospital with a 3-days history of progressive dyspnea on exertion, neck swelling, fatigue, persistent chest pain, pyrexia, and a cough that was occasionally productive of blood. The physical examination revealed a heart rate of 115 beats per minute (Sinus Rhythm), a respiratory rate of 25 breaths per minute and superficial vascular distention over the neck. Laboratory studies revealed elevated serum α -Fetoprotein (AFP) (5380 IU/ml) and D-dimer (481 ng/ml). A chest X-ray in the poster-anterior view, upon admission, depicted a suggestive right upper mediastinal mass (Image 1). Radiography was followed by contrast-enhanced CT scan that revealed a large, homogeneous mediastinal mass crossing into the anterior mediastinum and compressing–encasing the superior vena cava. It also showed signs of thrombosis of the left brachiocephalic vein, and multiple filling defects at the left pulmonary artery indicating embolism. Subcarinal lymphadenopathy, as well as enlarged lymph nodes of the right hilum was present (Image’s 2-5). On median sternotomy, a large non-resectable tumor was observed involving the innominate vein and the superior vena cava (Image 6). Great care was taken to remove as much tumor mass as possible. To decompress the superior vena cava, we had to perform an extensive resection and reconstruction of the cephalad part of the superior vena cava using homolog pericardium. A histopathological examination of a section of the mass revealed a mixed NSGCT



Image 5: CT-coronary plan of a Yolk sac tumor (yellow arrow) invading and occluding the vena cava superior (red arrow).




Image 6: Intra-operative view of huge Yolk sac tumor (arrows indicating).



Image 7: CT-axial plan of the Yolk sac tumor after chemotherapy.



Image 8: CT-axial plan of the seminoma.



Image 9: CT - sagittal plan of the seminoma.




Figure 1: Yolk sac Membranous and cytoplasmic positivity for AFP (alpha-fetoprotein) is seen in a significant number of neoplastic cells.




Figure 2: Yolk sac the tumor cells are diffusely positive for cytokeratin cocktail AE1/AE3.




Figure 3: Yolk sac the microcystic / macrocystic reticular pattern of growth (green arrows) is the most common finding in yolk sac tumors (>70% of cases). Nevertheless, it is possible to encounter more solid areas (black arrow). (H+E, x4).




Figure 4: Yolk sac the aforementioned growth patterns with Schiller-Duval type focal papillary structures in greater magnification. (H+E, x10).

(embryonal yolk sac/endodermal sinus tumour), containing also elements of embryonal carcinoma (Figures 1-6). The patient was placed on cisplatin-based chemotherapy (BEP regimen: cisplatin 50 mg/m² on days 1-2, etoposide 165 mg/m² on days 1-3, bleomycin 30 U on days 1, 8, and 15, every 3 weeks). Tumor markers were elevated for a-FP (214 ng/mL) and normal for β-HCG. The patient completed 4 cycles of chemotherapy and the subsequent chest CT (Image 7) revealed a partial remission of the mass (decrease >50% of the size). The a-FP was normal as well as the β-HCG. The remaining mass was inoperable so the patient was started on salvage chemotherapy with the TIP (paclitaxel, ifosfamide, cisplatin) regimen for 4 cycles. The post-chemo chest CT showed stable disease and the patient was referred to radiation oncologists for radiotherapy of the remaining tumor. Three months later aFP was found elevated and the CTs revealed multiple brain metastases. Whole brain radiation was performed and the patient was placed on gemcitabine (d1 and d8 every 21 days). Two months later the neurologic status deteriorated with new brain metastases and the patient passed away (19 months after the diagnosis).

Case - 2

The 2nd case we report is of a 42-year-old Caucasian male who sought the gastroenterology outpatient clinic complaining of

dysphagia for about 4 months. Laboratory findings were normal. X-ray with a contrast material (barium X-ray) and upper GI endoscopy were performed and the patient was treated for gastro-oesophageal reflux disease *via*. lifestyle changes and oral medication with proton-pump inhibitors. Two months later the symptom had precipitated and after oesophageal pH monitoring was performed, surgical treatment was decided. Before the surgery, an MRI scan of the chest showed a large mass of the anterior and middle mediastinum (Image's 8 & 9). PET showed marked uptake only in the mediastinal mass. Fine needle aspirates and core biopsies yielded a poorly

differentiated neoplasm. Blood tests for germ cell tumor markers showed a normal a-fetoprotein level and an elevated β -HCG level (31 mIU/ml). Thoracoscopy was performed to obtain sufficient tissue and histopathological examination of a section of the neoplasia revealed a seminoma (Figure 7-12). Testicular sonography was performed to look for an occult primary tumor. The testicles were normally positioned and symmetric in size and echogenicity. No mass was present. Thoracotomy revealed a dark, solid mass adherent to the pericardium, which was removed.




Figure 5: Yolk sac in certain areas of the neoplasm, it is possible for one to see eosinophilic, basement membrane material (green arrows), which is the main characteristic of the –so called-parietal pattern of the yolk sac tumor. This pattern is usually met with other growth patterns. (H+E, x20).




Figure 6: Yolk sac another characteristic of this tumor is the existence of conspicuous eosinophilic hyaline globules (green arrows), which can be seen either inside or outside the neoplastic cells. These globules are AFP- or A1-antitrypsin-positive. (H+E, x40).



Figure 7: Seminoma PLAP positivity (membranous staining pattern) in a significant number of tumor cells.




Figure 8: Seminoma the neoplastic cells show no positivity for Vimentin. On the contrary, the lymphocytes of the fibrous septa are indisputably positive.




Figure 9: Seminoma Positivity of tumor cells for CD117/c-kit (membranous & cytoplasmic staining pattern).




Figure 10: Seminoma the neoplastic cells are also positive (membranous staining pattern) for D2- 40 (podoplanin).




Figure 11: Mediastinal seminoma, like its gonadal counterpart, shows islands (green arrows) of large tumor cells with optically clear cytoplasm (due to large amounts of stored glycogen). These islands are separated by fibrous septa (black arrows) heavily infiltrated by non-neoplastic lymphocytes. (H + E x10).




Figure 12: Seminoma. Tumor cells of seminoma with clear cytoplasm (green arrows). Two prominent atypical mitotic figures (black arrows) (H+E x40).

Patient was placed on cisplatin-based chemotherapy (BEP regimen: cisplatin 50 mg/m² on days 1-2, etoposide 165 mg/m² on days 1-3, bleomycin 30U on days 1, 8, and 15, every 3 weeks). Patient completed 4 cycles of chemotherapy without major hematologic toxicity. A subsequent chest CT revealed a decrease in the size of the middle mediastinum remaining mass (from 5.5 cm × 2.5 cm to 2.3 cm × 1.5 cm). The fluorine-18, deoxy-2-fluoro-d-glucose Positron Emission Tomography (PET) - Computerized Tomography (CT) (PET-CT) was negative for viable disease. The remaining mass was inoperable so the patient was offered follow up with 3 monthly chest

Table 1: Malignant Causes of the Superior Vena Cava Syndrome*.

Tumor Type	Proportion % (range)	Suggestive Clinical Features
Non-small-cell lung cancer	50 (43-59)	History of smoking; often age >50 yr
Small-cell lung cancer	22 (7-39)	History of smoking; often age >50 yr
Lymphoma	12 (1-25)	Adenopathy outside the chest; often age <65 yr
Metastatic cancer	9 (1-15)	History of malignant condition
Germ-cell cancer	3 (0-6)	Usually, male sex and age <40 yr; elevated levels of β human chorionic gonadotropin or alpha- fetoprotein are common
Thymoma	2 (0-4)	Characteristic radiographic appearance on the
Mesothelioma	1 (0-1)	basis of the location of the thymus; frequently associated with the parathyroid syndromes (e.g., myasthenia gravis and pure red-cell aplasia)
Other cancers	1 (0-2)	History of asbestos exposure

CT and tumour markers (b-HCG, aFP, LDH) for the first year, 4monthly for the second year and twice a year for years 4, 5 and 6. Today, 76 months after the diagnosis the patient is in perfect health without any signs of relapse.

Discussion

Seminomas are slow growing, bulky tumors that invade locally early in the growth process. Patients may present with symptoms of compression of surrounding structures, like dyspnea, dysphagia cough and chest pain or even constitutional symptoms like fever and weight loss. Mediastinal adenopathy and Superior Vena Cava syndrome (SVC) syndrome may uncommonly occur. About 20% to 30% of patients are asymptomatic. The most common clinical features that may suggest this rare entity are summarized in Table 1. Management of the superior vena cava syndrome associated with malignant conditions involves both treatment of the cancer and relief of the symptoms of obstruction. Most data regarding management of the superior vena cava syndrome are from case series; randomized trials are scarce. The median life expectancy among patients with obstruction of the superior vena cava is approximately 6 months; but estimates vary widely according to the underlying malignant conditions. Surgical bypass grafting is infrequently used to treat the superior vena cava syndrome. The rates of illness after resection and reconstruction range between 80 to 90% with an underlying mortality of approximately 5%. Rates of occlusion of the superior vena cava of 10% have been reported after surgical reconstruction [12-14].

Management is guided by the severity of the symptoms and the underlying malignant conditions as well as by the anticipated response to treatment. For example, in patients with lymphoma, small-cell lung cancer, or germ-cell tumors, the clinical response to systemic chemotherapy alone typically is rapid [15-24]. Mediastinal non-seminomatous germ cell tumors are more frequent in individuals with Klinefelter syndrome and are associated with a risk of subsequent development of hematologic neoplasia that is not treatment related [25,26]. Approximately 50% of patients with mediastinal non-seminomatous germ cell tumors will survive with appropriate management [27]. Yolk sac tumor is a primitive malignant germ cell tumor. Some of the histological patterns of yolk sac tumor recapitulate the various phases in the development of normal yolk sac. The usual age group affected is children and young adults. Extra gonadal non-seminomatous germ cell tumors are highly sensitive to cisplatin-based chemotherapy regimens [28]. In fact, during the last three decades, the clinical outcome of NSGCT has been dramatically improved since the introduction of cisplatin-based chemotherapy. Pure seminoma is sensitive to radiotherapy and the prognosis is good [29]. However, the prognosis for the NSGCT is poor [30], 5-year

overall survival rate of mediastinal NSGCT is much lower than that of gonadal NSGCT [25-27]. Primary mediastinal malignant GCT is often prone to be misdiagnosed, because of their nonspecific clinical symptoms. Although the success of chemotherapy regimens in Primary mediastinal malignant GCT is important, skilled thoracic surgery even aggressive resection is an equally important component for successful multidimensional therapy [31].

Conclusion

The superior vena cava syndrome is often clinically striking. Most of cases are due to malignant conditions. Treatment planning should be multidisciplinary. Relevant data on the tumor type and stage of the cancer should be used to guide the therapy (i.e., chemotherapy or radiotherapy or both or, in occasional cases, surgery alone or in combination with other therapies); these types of therapy can relieve the symptoms of obstruction of the superior vena cava in the vast majority of patients. High risk is partially related to tumor bulk, to chemotherapy resistance, and to a predisposition to develop hematologic neoplasia and other nongerm cell malignancies.

Funding

All sources of funding for the research reported are declared. The roles of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript are declared.

Consent for Publication

Written informed consent was obtained from our patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal at any time.

Authors' Contributions

SID participated in sequence alignment, designing the case report and drafting the manuscript. MS participated in the design of the case report and drafting the manuscript GK participated in the design of the case report, AK participated in the design of the case report, DP participated in the design of the case report. CT participated in the design of the case report. CM participated in the design and culled relevant information. All authors read and approved the final manuscript.

References

- Moran CA, Suster S, Przygodzki RM, Koss MN. Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases. *Cancer*. 1997;80(4):691-8.
- Polansky SM, Barwick KW, Ravin CE. Primary mediastinal seminoma.

- Am J Roentgenol. 1979;132:17-21.
3. Fizazi K, Culine S, Droz JP, Terrier-Lacombe MJ, Theodore C, Wibault P, et al. Initial management of primary mediastinal seminoma: radiotherapy or cisplatin based chemotherapy? *Eur J Cancer*. 1998;34(3):347-52.
 4. Friedman NB. The comparative morphogenesis of extragenital and gonadal teratoid tumors. *Cancer*. 1951;4(2):265-76.
 5. Abell MR, Fayos IV, Lampe L. Retroperitoneal germinomas (seminomas) without evidence of testicular involvement. *Cancer*. 1965;18:273-90.
 6. Kitami A, Suzuki T, Susuki S, Hori G. Primary seminoma in the middle mediastinum: case report in a 69-year-old male. *Jpn J Clin Oncol* 1998;28(2):142-4.
 7. Knapp RH, Hurt RD, Payne WS, Farrow GM, Lewis BD, Hahn RG, et al. Malignant germ cell tumors of the mediastinum. *J Thorac Cardiovasc Surg*. 1985;89:82-9.
 8. Williams M, Gee DC, Cooper E, Dickinson P, Sandeman TF, Sum AC. Thymic seminoma and myasthenia gravis. *J Clin Neuro-Ophthalmol*. 1985;5(4):254-7.
 9. Friedman N. The function of the primordial germ cell in extragonadal tissues. *Int J Andro* 1987;10(1):43-9.
 10. Ulbright TM. Germ cell tumors of the gonads: A selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. *Mod Pathol*. 2005;18(Suppl 2):561-79.
 11. Yang GC, Hwang SJ, Yee HT. Fine-needle aspiration cytology of unusual germ cell tumors of the mediastinum: Atypical seminoma and parietal yolk sac tumor. *Diagn Cytopathol*. 2002;27(2):69-74.
 12. Magnan PE, Thomas P, Guidicelli R, Fuentes P, Branchereau A. Surgical reconstruction of the superior vena cava. *Cardiovasc Surg*. 1994;2(5):598-604.
 13. Bacha EA, Chapelier AR, Macchiarini P, Fadel E, Dartevelle PG. Surgery for invasive mediastinal tumors. *Ann Thorac Surg*. 1998;66(1):234-9.
 14. Dettlerbeck FC, Jones DR, Kernstine KH, Naunheim KS. Lung cancer: special treatment issues. *Chest* 2003;123(Suppl 1):244S-58S.
 15. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome: the myth - the facts. *Am Rev Respir Dis*. 1990;141(5pt 1):1114-8.
 16. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction: is it a medical emergency? *Am J Med*. 1981;70(6):1169-74.
 17. Marcy PY, Magne N, Bentolila F, Drouillard J, Bruneton JN, Descamps B. Superior vena cava obstruction: is stenting necessary? *Support Care Cancer*. 2001;9(2):103-7.
 18. Greillier L, Barlesi F, Doddoli C, Durieux O, Torre JP, Gimenez C, et al. Vascular stenting for palliation of superior vena cava obstruction in non-small-cell lung cancer patients: a future 'standard' procedure? *Respiration*. 2004;71(2):178-83.
 19. Tanigawa N, Sawada S, Mishima K, Okuda Y, Mizukawa K, Ohmura N, et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors: comparison with conventional treatment. *Acta Radiol*. 1998;39(6):669-74.
 20. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. *Int J Radiat Oncol Biol Phys*. 1987;13(4):531-9.
 21. Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. *Am J Surg*. 1990;160(2):207-11.
 22. Rice TW, Rodriguez RM, Barnette R, Light RW. Prevalence and characteristics of pleural effusions in superior vena cava syndrome. *Respirology*. 2006;11(3):299-305.
 23. Nicholson AA, Ettles DF, Arnold A, Greenstone M, Dyet JF. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. *J Vasc Interv Radiol*. 1997;8(5):781-8.
 24. Dettlerbeck FC, Parsons AM. Thymic tumors. *Ann Thorac Surg*. 2004;77(5):1860-9.
 25. Nichols CR, Heerema NA, Palmer C, Loehrer PJ Sr, Williams SD, Einhorn LH. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. *J Clin Oncol*. 1987;5(8):1290-4.
 26. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. *N Engl J Med*. 1990;322(20):1425-9.
 27. Nichols CR, Saxman S, Williams SD, Loehrer PJ, Miller ME, Wright C, et al. Primary mediastinal nonseminomatous germ cell tumors. A modern single institution experience. *Cancer*. 1990;65(7):1641-6.
 28. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis. *J Clin Oncol*. 2002;20(7):1864-73.
 29. Kersh CR, Constable WC, Hahn SS, Spaulding CA, Eisert DR, Jenrette JM, et al. Primary malignant extragonadal germ cell tumors. An analysis of the effect of radiotherapy. *Cancer*. 1990;65(12):2681-5.
 30. Kay PH, Wells FC, Goldstraw P. A multidisciplinary approach to primary nonseminomatous germ cell tumors of the mediastinum. *Ann Thorac Surg*. 1987;44(6):578-82.
 31. Liu Y, Wang Z, Peng Z-M, Yu Y. Management of the primary malignant mediastinal germ cell tumors: experience with 54 patients. *Diagn Pathol*. 2014;9:33.